Valuation: Simulations Plus, Inc.

Market Cap 369M 324M 300M 276M 522M 35.33B 532M 3.57B 1.4B 17.35B 1.39B 1.36B 59.91B P/E 2026 *
43.5x
P/E 2027 * 39.9x
Enterprise Value 369M 324M 300M 276M 522M 35.33B 532M 3.57B 1.4B 17.35B 1.39B 1.36B 59.91B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 4.28x
Free-Float
82.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.05%
1 week-0.60%
Current month-0.33%
1 month+11.83%
3 months+40.93%
6 months-8.15%
Current year+0.11%
1 week 18.22
Extreme 18.22
18.4
1 month 16.28
Extreme 16.28
18.68
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.44
Extreme 7.44
90.92
Manager TitleAgeSince
Chief Executive Officer 67 25/06/2018
Director of Finance/CFO 63 30/11/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 16/07/1996
Chairman 76 16/12/2024
Director/Board Member 58 02/12/2014
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Executive/Senior Manager

-1,000 0.0050%
06-30Sell

Founder

-4,177 0.0207%
06-15Fiscal year

Executive/Senior Manager

22,050 0.1094%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-0.60%+7.61%-61.14% 369M
+3.52%+2.50%-28.66%-5.72% 31.97B
-2.08%-7.54%-38.54%+197.51% 14.42B
-0.42%-2.14%-22.19%+69.65% 5.7B
-2.10%-3.50% - - 2.26B
+3.92%+3.18%+62.70%-36.39% 2.12B
-0.31%-15.60% - - 1.83B
-1.20%-2.10%-30.72% - 1.09B
-2.81%-6.14%+47.16%+105.51% 922M
-1.34%-2.31%-35.86%+245.45% 821M
Average -0.28%-3.43%-4.81%+73.55% 6.15B
Weighted average by Cap. +1.27%-3.16%-25.81%+57.91%

Financials

2026 *2027 *
Net sales 81.87M 71.81M 66.51M 61.2M 116M 7.84B 118M 793M 311M 3.85B 307M 301M 13.29B 86.26M 75.66M 70.07M 64.47M 122M 8.26B 124M 835M 328M 4.05B 324M 317M 14B
Net income 9.53M 8.36M 7.74M 7.13M 13.48M 912M 13.74M 92.31M 36.2M 448M 35.8M 35.02M 1.55B 10.18M 8.93M 8.27M 7.61M 14.39M 974M 14.67M 98.58M 38.66M 479M 38.23M 37.4M 1.65B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
13/07/26 US$18.25 +0.05% 394,365
10/07/26 US$18.24 -0.55% 423,570
09/07/26 US$18.34 +0.38% 403,218
08/07/26 US$18.27 -0.05% 397,537
07/07/26 US$18.28 -0.44% 352,032
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.25USD
Average target price
17.25USD
Spread / Average Target
-5.48%

Quarterly revenue - Rate of surprise